Circulating Omentin-1 in Obesity and Metabolic Syndrome Status Compared to Control Subjects
- corresponding Author:
- Arash Hossein-nezhad
Endocrinology and Metabolism Research institute
North Kargar Ave., 5th Floor
Shariati Hospital Tehran 14114, Iran
Tel: (+98 21) 88220037-8
Fax: (+98 21) 882220054
E-mail: [email protected]
Received Date: October 11, 2011; Accepted Date: January 06, 2012; Published Date: January 09, 2012
Citation: Hossein-nezhad A, Mirzaei K, Alatab S, Ahmadivand Z, Najmafshar A (2012) Circulating Omentin-1 in Obesity and Metabolic Syndrome Status Compared to Control Subjects. Endocrinol Metabol Syndrome S1:008. doi: 10.4172/2161-1017.S1-008
Copyright: © 2012 Hossein-nezhad A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Background and aim: The goal of this study was to investigate the association between omentin-1 and different biochemical and anthropometric parameters in obese and non-obese, also in patients with metabolic syndrome compared to the healthy control group.
Methods: A total of 81 women were included in the current case-control study. Based on their BMI they were divided into obese and non-obese groups and according to WHO criteria for metabolic syndrome they were divided in to metabolic syndrome group and healthy subjects. Fasting blood sample was collected to determine biochemical indicators and insulin resistance and sensitivity indices (HOMA-IR and Quicki). Omentin-1 plasma level was assessed by ELISA. Association of omentin-1 with biochemical markers was studied. Body composition was measured using Body composition analyzer BC-418MA- Tanita.
Results: Levels of omentin-1 were lower in obese than non-obese subjects. It was also lower in patients with metabolic syndrome than in healthy ones. In correlation analysis, omentin-1 was associated with waist circumference, fat percent and fat mass and nearly visceral fat. But there was no significant relation between omentin and any insulin resistance indices.
Conclusions: In conclusion, omentin-1 is an adipokine closely associated with visceral obesity, but not with insulin resistance, and glucose metabolism; its serum concentration is decreased in the state of obesity and the regulation of omentin-1 production in adipose tissue is probably multifactorial. Future analysis of omentin’s biological actions, and measurement of omentin-1 levels in the omental depot as well as in the circulation of humans with or without obesity and its co morbidities, will help to define its role in the pathogenesis of these diseases.